Close

Zentalis Pharmaceuticals (ZNTL) Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. ENPH
3. TXN
4. BA
5. SPOT
6. META
7. V
8. IBM
9. KMB
10. HCP


Go back to Zentalis Pharmaceuticals (ZNTL) Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy
(NASDAQ: ZNTL) Delayed: 11.77 -0.8 (6.36%)
Previous Close $12.57    52 Week High $ 
Open $12.50    52 Week Low $ 
Day High $12.59    P/E N/A 
Day Low $11.63    EPS $ 
Volume 854,473